Pharmacological and non-pharmacological interventions for cough in adults with respiratory and non-respiratory diseases: A systematic review of the literature

Q3 · MEDICINE

Review

Author: A. Caress ; G. Bryan ; A. Molassiotis ; J. Smith ; C. Bailey

The management of cough in adults with respiratory and non-respiratory illnesses is suboptimal and based mostly on clinical opinions rather than evidence. A systematic review was carried out assessing all trials in adult patients with respiratory and non-respiratory diseases (excluding cancer) that had chronic cough as primary or secondary outcome. A total of 1177 trials were retrieved and 75 met the criteria for inclusion in the review. The vast majority were in patients with asthma and chronic obstructive pulmonary disease (COPD). Cough was the primary outcome in less than one-quarter of the studies. The measurement of cough was variable, mostly using unvalidated scales or being part of an overall 'symptoms' score. Positive results were overall seen with the use of corticosteroids, leukotriene receptor antagonists, mast cell stabilizers, ipratropium bromide, neltenexine, iodinised glycerol and lidocaine. Speech pathology training and symptom monitoring through SMS messages (accompanied by treatment adjustments) have also shown promise. Evidence for established anti-tussive agents such as codeine was scarce, with positive studies from the 1960s, whilst more recent studies showed no effect in patients with COPD. Many studies had conflicting results. It is imperative that the management of cough and its evidence base be improved, using higher quality research designs and with cough being the primary outcome of trials.

01 May 2007·Biochemical and Biophysical Research CommunicationsQ3 · BIOLOGY

Action of neltenexine on anion secretion in human airway epithelia

Q3 · BIOLOGY

Article

Author: Shinsaku Tokuda ; Yoshinori Marunaka ; Naomi Niisato ; Hiroaki Miyazaki ; Yoshinobu Iwasaki ; Isao Hasegawa ; Akiyuki Taruno ; Ken-ichi Nakajima

Neltenexine has been applied to human lung diseases such as chronic obstructive pulmonary disease (COPD) as a mucolytic agent. However, we have no information on the neltenexine action in bronchial epithelial cells. We studied the neltenexine action on the ion transport in human submucosal serous Calu-3 cells. Under a hyper-secreting condition caused by terbutaline (a beta2-adrenergic agonist), neltenexine diminished anion secretion by inhibiting the Cl- and HCO3- uptake via Na+/K+/2Cl- cotransporter and Na+/HCO3- cotransporter without blockade of the cystic fibrosis transmembrane conductance regulator (CFTR) channel, and also diminished anion secretion via stimulation of Cl-/HCO3- exchanger, which facilitates the extrusion of more CFTR-permeant anion, Cl-, with the uptake of less CFTR-permeant anion, HCO3-. Thus, neltenexine reduced the hyper-secretion to keep an appropriate fluid level in the airway, providing a possibility that neltenexine can be an effective drug in airway obstructive diseases by decreasing the airway resistance under a hyper-secreting condition.

01 Aug 2001·Minerva medicaQ4 · MEDICINE

Oral neltenexine in patients with obstructive airways diseases: an open, randomised, controlled comparison versus sobrerol.

Q4 · MEDICINE

Article

Author: Fadda, G

BACKGROUNDThe synthetic mucolytic neltene-xine is an amide derivative of ambroxol and thiophencarboxylic acid. The aim of this open, randomised, controlled study versus sobrerol was to evaluate the efficacy and tolerability of neltenexine (oral granules in sachets) as compared with sobrerol (oral granules in sachets), administered to patients with obstructive airways disease.METHODSThirty male and female patients were recruited. The exclusion criteria were allergy to neltenexine or sobrerol, an assessed diagnosis of severe bronchospasm requiring beta2-agonists, corticosteroids or aminophylline, pregnant or nursing women, cystic fibrosis, active tuberculosis or an assessed diagnosis of bronchiectasis. No infections of other organs (such as urinary tract infections) were present at baseline. Concomitant treatment with antitussives or other mucolytic agents was not allowed during the course of the study. Fifteen patients were randomised to treatment with neltenexine, 1 sachet thrice daily for 20 days orally (neltenexine group) and 15 patients to treatment with sobrerol, 1 sachet thrice daily for 20 days orally (sobrerol group). The efficacy parameters were: sputum characteristics and volume, difficulty in expectorating, cough, dyspnoea, pulmonary auscultation. Tolerability was monitored and adverse events were reported.RESULTSThe study highlighted that neltenexine has a good efficacy in the treatment of patients with obstructive airways disease entailing significant impairment of clinical parameters.CONCLUSIONSNeltenexine can be an effective therapeutic alternative to sobrerol.

100 Deals associated with Neltenexine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Neltenexine	R05CB14	DB13239

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cough	IT	Istituto Biochimico Italiano Giovanni Lorenzini SpA	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis